drugset / Trial / NCT05177211
Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)
Phase 2
Completed
25 enrolled
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to evaluate the effectiveness, safety, and tolerability of a study drug called fedratinib in participants with myelodysplastic/myeloproliferative neoplasms (MDS/MPNs) and chronic neutrophilic leukemia (CNL).
Timeline
- Start
- 2022-03-01
- Primary completion
- 2025-04-10
- Completion
- 2026-01-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fedratinib | Small molecule | 400 mg | Oral |